Inotuzumab Ozogamicin

Inotuzumab ozogamicin is an antibody-drug conjugate used to treat certain patients with B-cell precursor acute lymphoblastic leukemia (ALL), a cancer in which immature B lymphocytes multiply abnormally. It combines a humanized monoclonal antibody that recognizes the CD22 protein on B cells with ozogamicin, a potent cytotoxic agent derived from calicheamicin. After the antibody binds to CD22 on leukemia cells, the complex is taken into the cell, where the cytotoxic component is released. This agent damages DNA, causing leukemia cells to die. By directing the cytotoxic substance toward CD22-expressing cells, the medicine provides a targeted treatment approach, although it can also affect normal B cells and cause significant adverse effects. Inotuzumab ozogamicin is administered by intravenous infusion under the supervision of a qualified oncology team. It is primarily used when B-cell precursor ALL has returned after treatment or has not responded adequately to previous therapy. Treatment selection depends on disease characteristics, previous therapies, overall health, liver function, and the possibility of subsequent treatments, including hematopoietic stem cell transplantation. Close monitoring is particularly important because the medicine can cause serious liver injury, including hepatic veno-occlusive disease, also known as sinusoidal obstruction syndrome. Blood counts, liver tests, infusion reactions, and other treatment-related complications require careful assessment throughout therapy.

Inotuzumab ozogamicin was developed as a targeted treatment for CD22-positive B-cell malignancies. Its development was supported by clinical research investigating whether a CD22-directed antibody linked to a cytotoxic agent could improve outcomes in patients with relapsed or refractory acute lymphoblastic leukemia. The pivotal phase III INO-VATE ALL trial compared inotuzumab ozogamicin with standard-of-care chemotherapy in adults with relapsed or refractory disease and demonstrated higher complete remission rates with the medicine. The United States Food and Drug Administration (FDA) approved the treatment for adults with relapsed or refractory B-cell precursor ALL in August 2017. The European Commission authorized it in the European Union in June 2017. In March 2024, the FDA expanded its approval to include pediatric patients aged one year and older with relapsed or refractory CD22-positive B-cell precursor ALL. Regulatory indications and age eligibility vary by jurisdiction, so current local prescribing information should be consulted before treatment.

Inotuzumab ozogamicin is used for the treatment of relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia. In adults, the treatment may be considered when leukemia returns after previous therapy or does not respond adequately to prior treatment. In the United States, the approved indication also includes eligible pediatric patients aged one year and older. For adults with Philadelphia chromosome-positive disease, applicable prescribing information may require failure of at least one tyrosine kinase inhibitor before treatment. Inotuzumab ozogamicin is generally administered as monotherapy rather than as part of a conventional multi-drug chemotherapy regimen, although treatment planning may include subsequent therapies such as stem cell transplantation. Selection depends on CD22 expression, previous treatment, disease status, transplant eligibility, and individual risk factors. Its use should be guided by a hematologist or oncology specialist familiar with acute leukemia.

Inotuzumab ozogamicin is administered by intravenous infusion, usually over one hour, in a specialist healthcare setting. Dosing is based on body surface area and is divided across three administrations on days 1, 8, and 15 of a treatment cycle. For adults, the usual total dose during the first cycle is 1.8 mg/m², given as 0.8 mg/m² on day 1 and 0.5 mg/m² on days 8 and 15. In subsequent cycles, the usual total dose is 1.5 mg/m² per cycle, divided into three administrations of 0.5 mg/m² each, with adjustments according to response and tolerability. The first cycle generally lasts three weeks but may be extended when remission has not been achieved and toxicity requires additional recovery time. Treatment is generally limited to six cycles in patients who do not proceed to transplantation. For patients proceeding to transplantation, treatment is usually limited to two cycles, with a possible third cycle in selected circumstances. Premedication, blood count monitoring, liver function testing, and dose delays or modifications may be necessary.

Common adverse effects of inotuzumab ozogamicin include low platelet counts, reduced white blood cell counts, anemia, infections, fatigue, fever, nausea, headache, abdominal discomfort, and bleeding. Abnormal liver enzyme levels may also occur. Patients may experience infusion-related reactions, including chills, fever, or breathing difficulties during or shortly after administration. Some adverse effects arise from reduced blood cell production, increasing the risk of infection, bruising, or bleeding. The severity and frequency of side effects vary depending on the patient's health, previous treatments, disease status, and other medicines being used. Supportive care, blood tests, infection prevention measures, and appropriate treatment adjustments can help manage many complications. Patients should promptly report new symptoms to their oncology team rather than changing or stopping treatment independently.

A major safety concern with inotuzumab ozogamicin is hepatic veno-occlusive disease, also called sinusoidal obstruction syndrome. This potentially life-threatening complication involves damage to small blood vessels in the liver and may cause jaundice, painful liver enlargement, fluid retention, and rapid weight gain. The risk is particularly important in patients who subsequently undergo hematopoietic stem cell transplantation. Other serious complications include severe bone marrow suppression, serious infections, bleeding, infusion-related reactions, and tumour lysis syndrome, which can occur when cancer cells break down rapidly. QT interval prolongation and electrolyte abnormalities may also require attention in susceptible patients. Treatment may need to be delayed, reduced, or discontinued depending on the severity of toxicity and laboratory findings. Liver function and clinical signs of hepatic injury should be monitored closely during therapy and before transplantation. Any decision to continue treatment must balance the expected benefit against the risk of serious complications.

Before starting inotuzumab ozogamicin, clinicians should assess complete blood counts, liver function, kidney function, electrolytes, infection status, previous treatment exposure, and the patient's transplant history or plans. Patients with existing liver disease or a history of hepatic veno-occlusive disease may require particular caution. Liver injury risk should be considered when selecting subsequent conditioning regimens for stem cell transplantation. Medicines that prolong the QT interval or disturb electrolyte balance may increase cardiac risk, while other medicines that affect liver function may complicate safety monitoring. All prescription medicines, non-prescription products, and supplements should be reviewed by the treating team. Pregnancy status and reproductive risks should be discussed where relevant, because the medicine may harm an unborn child. Effective contraception should be used in accordance with current prescribing guidance. Vaccination plans, particularly live vaccines during periods of significant immunosuppression, should be reviewed with the oncology team. Dose decisions should account for blood counts, liver test results, treatment response, and the patient's overall condition.

Prescribers should confirm the diagnosis of B-cell precursor ALL and establish CD22 expression using appropriate diagnostic testing before initiating treatment. Baseline evaluation should include complete blood counts, liver function, electrolytes, assessment for active infection, and review of prior hepatotoxic therapies. The team should establish a monitoring plan for hepatic veno-occlusive disease, particularly when stem cell transplantation is being considered. Premedication and observation during and after infusion should follow the applicable prescribing information and institutional protocol. Pharmacists should verify the body-surface-area-based dose, treatment-cycle schedule, dose adjustments, and compatibility and preparation requirements according to the approved product information. Electrolyte abnormalities and medicines associated with QT prolongation should be reviewed before and during treatment. Coordination between hematologists, transplant specialists, oncology pharmacists, and nursing staff is important to ensure appropriate timing of treatment, early recognition of toxicity, and safe transitions to subsequent therapy. Patients should receive clear counselling about infection symptoms, unusual bleeding, jaundice, abdominal swelling, rapid weight gain, and infusion reactions that require urgent medical assessment.